ArticleSurgery today2026
Impact of sequential perioperative chemotherapy for high-risk colorectal liver metastases.
Article in Surgery today, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe impact of perioperative chemotherapy, including neoadjuvant chemotherapy (NAC) and adjuvant chemotherapy (AC), given for resectable colorectal liver metastasis (CLM) remains unclear. This study evaluates the optimal strategy for managing high-risk CLM.
methodsThe subjects of this retrospective study were patients who underwent liver resection for initially resectable CLM between 2006 and 2021. High-risk status was defined by four or more metastases, a tumor size ≥ 5 cm, or the presence of resectable extrahepatic disease. Among 363 eligible patients, 293 received NAC and 70 underwent upfront surgery. Propensity score matching (PSM) created balanced groups of 70 each.
resultsAmong the patients who received NAC, seven did not undergo resection because they had disease progression. Intention-to-treat analysis revealed significantly longer median progression-free survival (PFS) (1.1 vs. 0.6 years, p < 0.001) and overall survival (OS) (5.2 vs. 4.3 years, p = 0.044) in the NAC group. Matched analysis confirmed superior PFS (1.2 vs. 0.6 years, p = 0.004) and a favorable OS trend (5.4 vs. 4.3 years, p = 0.164). Completion of the perioperative sequence of NAC, surgery, and AC was associated with the most favorable outcomes.
conclusionAchieving a sequential strategy of NAC, surgery, and AC may improve the long-term survival of patients with high-risk CLM, supporting its potential as a standard treatment strategy.
Indexed as
Identifiers
41015621What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.